McKesson Corporation (BMV:MCK)
Mexico
· Delayed Price · Currency is MXN 13,740
0.00 (0.00%)
At close: Jun 24, 2025, 2:00 PM CST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
Other Revenue seg1 | 11.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Solutions | 11.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Solutions Growth | 0.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Pharmaceutical | 327.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Pharmaceutical Growth | 17.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prescription Technology Solutions | 5.22B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prescription Technology Solutions Growth | 9.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International | 14.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Growth | 4.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
Medical Surgical Solutions Capital Expenditures | 163.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Solutions Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Capital Expenditures seg1 | 15.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Capital Expenditures seg1 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Pharmaceutical Capital Expenditures | 241.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Pharmaceutical Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prescription Technology Solutions Capital Expenditures | 11.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prescription Technology Solutions Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Capital Expenditures | 107.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
Medical Surgical Solutions Operating Profit | 773.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Solutions Operating Profit Growth | -18.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 | -522.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 Growth | 268.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Pharmaceutical Operating Profit | 4.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
US Pharmaceutical Operating Profit Growth | 43.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prescription Technology Solutions Operating Profit | 875.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prescription Technology Solutions Operating Profit Growth | 4.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Operating Profit | -213.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Operating Profit Growth | -166.77% |
Log In |
Log In |
Log In |
Log In | Upgrade
|